Fredun Pharmaceuticals Ltd Financials
Company Logo

Fredun Pharmaceuticals Ltd Financial Statement

Fredun Pharmaceuticals Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Sep 2025
Revenue145.29
Operating Expense122.96
Net Profit9.73
Net Profit Margin6.70
Earning Per Share20.61
EBIDTA22.33
Effective Tax Rate14.64

Fredun Pharmaceuticals Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Total Revenue Annual348.16
Operating Expenses Annual310.17
Operating Profit Annual38.90
Interest Annual13.65
Depreciation3.80
Net Profit Annual15.62
Tax Annual5.83

Fredun Pharmaceuticals Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the Beginning3.44
Cash Flow from Operations-0.44
Cash Flow from Investing-7.64
Cash Flow from Financing5.99
Cash Flow at the End1.35

Fredun Pharmaceuticals Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)11.17
PBIT Margin (%)10.08
PBT Margin (%)9.34
Net PROFIT Margin (%)4.49
Return On Networth / Equity (%)14.34
Return On Networth /Employed (%)16.95
Return On Assets (%)7.54
Total Debt / Equity (X)0.88
Asset Turnover Ratio (%)1.68

Fredun Pharmaceuticals Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Fixed Assets Annual46.57
Total Current Assets Annual257.20
Non Current Assets Annual50.40
Total Shareholders Funds Annual121.47
Total Assets Annual307.60

Fredun Pharmaceuticals Ltd Earning Calls

EPS (INR)

Expected

19.98

Reported

19.98

Surprise

0.00%

Jun 2025

EPS beaten by 0.00%

Mar 2025

EPS beaten by -0.07%

Dec 2024

EPS beaten by 0.00%

FAQS on Fredun Pharmaceuticals Ltd Financials

As of Nov 15, 2025, Fredun Pharmaceuticals Ltd has a market capitalization of 315.67 Cr. Value Research classifies it as a Small-Cap company.

Yes, Fredun Pharmaceuticals Ltd is not with a debt-to-equity ratio of 1.18.

In FY 2024 , Fredun Pharmaceuticals Ltd recorded a total revenue of approximately 451.71 Cr marking a significant milestone in the company's financial performance.

Fredun Pharmaceuticals Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately -0.1% and 0.2% annually, respectively..

Fredun Pharmaceuticals Ltd's current PE ratio is 15.17.

Fredun Pharmaceuticals Ltd's ROCE averaged 15.5% from the FY ending March 2023 to 2025, with a median of 15.5%. It peaked at 16.5% in March 2025, reflecting strong capital efficiency over the period..

Fredun Pharmaceuticals Ltd's latest EBIT is Rs. 50.65 Cr, surpassing the average EBIT of Rs. 37.51 Cr over the 5 years..

Join the Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions